Dr. Reddy’s Russian arm hit with reduced VAT penalty, seen as immaterial

Dr. Reddy’s Laboratories Ltd. ( (IN:DRREDDY) ) has shared an announcement.

Dr. Reddy’s Laboratories has disclosed that its step-down wholly owned subsidiary in Russia, Dr. Reddy’s Laboratories LLC, has received a final penalty decision from the Interdistrict Inspectorate of the Federal Tax Service of Russia. The case relates to the levy of value added tax after the reclassification of certain marketing services as taxable, with the tax authority imposing a reduced penalty of RUB 9.27 million (about INR 11.40 million), down from an originally quantified RUB 20.09 million.

According to the company’s assessment, the finalized penalty will not have a material impact on Dr. Reddy’s consolidated financials, operations or other corporate activities. The disclosure, made under Indian listing regulations to stock exchanges in India and the U.S., signals closure of this specific Russian tax dispute while indicating that the financial exposure remains limited for shareholders and other stakeholders.

More about Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in India, engaged in the development, manufacture and marketing of generics, branded formulations and active pharmaceutical ingredients. The company serves key regulated and emerging markets, including Russia, where it operates through subsidiaries to distribute medicines and related healthcare products.

Average Trading Volume: 97,699

Technical Sentiment Signal: Buy

Current Market Cap: 1027.8B INR

See more insights into DRREDDY stock on TipRanks’ Stock Analysis page.